Global Nanotechnology for Healthcare 麻豆原创 Research Report 2023

Publication ID:

PB502234481

Publication Date:

February 22, 2023

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

It is defined as the study of controlling, manipulating and creating systems based on their atomic or molecular specifications. As stated by the US National Science and Technology Council, the essence of nanotechnology is the ability to manipulate matters at atomic, molecular and supra-molecular levels for creation of newer structures and devices. Generally, this science deals with structures sized between 1 to 102 nanometer (nm) in at least one dimension and involves in modulation and fabrication of nanomaterials and nanodevices.
Highlights
The global Nanotechnology for Healthcare market was valued at US$ 213190 million in 2022 and is anticipated to reach US$ 256040 million by 2029, witnessing a CAGR of 3.1% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The industry is crowded with producers and fierce competition. The U.S. has the highest share of income by region, at more than 48 percent.The key manufacturers are Amgen, Teva Pharmaceuticals, Abbott, UCB, Roche, Celgene, Sanofi, Merck & Co, Biogen, Stryker, Gilead Sciences, Pfizer, 3M Company, Johnson & Johnson, Smith & Nephew, Leadiant Biosciences, Kyowa Hakko Kirin, Shire, Ipsen, Endo International etc. Top 3 companies occupied about 4% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nanotechnology for Healthcare, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanotechnology for Healthcare.
The Nanotechnology for Healthcare market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Nanotechnology for Healthcare market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Nanotechnology for Healthcare companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Amgen
Teva Pharmaceuticals
Abbott
UCB
Roche
Celgene
Sanofi
Merck & Co
Biogen
Stryker
Gilead Sciences
Pfizer
3M Company
Johnson & Johnson
Smith & Nephew
Leadiant Biosciences
Kyowa Hakko Kirin
Shire
Ipsen
Endo International
Segment by Type
Nanomedicine
Nano Medical Devices
Nano Diagnosis
Other
Segment by Application
Anticancer
CNS Product
Anti-infective
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nanotechnology for Healthcare companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Nanotechnology for Healthcare 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Nanomedicine
1.2.3 Nano Medical Devices
1.2.4 Nano Diagnosis
1.2.5 Other
1.3 麻豆原创 by Application
1.3.1 Global Nanotechnology for Healthcare 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Anticancer
1.3.3 CNS Product
1.3.4 Anti-infective
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Nanotechnology for Healthcare 麻豆原创 Perspective (2018-2029)
2.2 Nanotechnology for Healthcare Growth Trends by Region
2.2.1 Global Nanotechnology for Healthcare 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Nanotechnology for Healthcare Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Nanotechnology for Healthcare Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Nanotechnology for Healthcare 麻豆原创 Dynamics
2.3.1 Nanotechnology for Healthcare Industry Trends
2.3.2 Nanotechnology for Healthcare 麻豆原创 Drivers
2.3.3 Nanotechnology for Healthcare 麻豆原创 Challenges
2.3.4 Nanotechnology for Healthcare 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Nanotechnology for Healthcare Players by Revenue
3.1.1 Global Top Nanotechnology for Healthcare Players by Revenue (2018-2023)
3.1.2 Global Nanotechnology for Healthcare Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Nanotechnology for Healthcare 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Nanotechnology for Healthcare Revenue
3.4 Global Nanotechnology for Healthcare 麻豆原创 Concentration Ratio
3.4.1 Global Nanotechnology for Healthcare 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Nanotechnology for Healthcare Revenue in 2022
3.5 Nanotechnology for Healthcare Key Players Head office and Area Served
3.6 Key Players Nanotechnology for Healthcare Product Solution and Service
3.7 Date of Enter into Nanotechnology for Healthcare 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Nanotechnology for Healthcare Breakdown Data by Type
4.1 Global Nanotechnology for Healthcare Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Nanotechnology for Healthcare Forecasted 麻豆原创 Size by Type (2024-2029)
5 Nanotechnology for Healthcare Breakdown Data by Application
5.1 Global Nanotechnology for Healthcare Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Nanotechnology for Healthcare Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Nanotechnology for Healthcare 麻豆原创 Size (2018-2029)
6.2 North America Nanotechnology for Healthcare 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Nanotechnology for Healthcare 麻豆原创 Size by Country (2018-2023)
6.4 North America Nanotechnology for Healthcare 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Nanotechnology for Healthcare 麻豆原创 Size (2018-2029)
7.2 Europe Nanotechnology for Healthcare 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Nanotechnology for Healthcare 麻豆原创 Size by Country (2018-2023)
7.4 Europe Nanotechnology for Healthcare 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Nanotechnology for Healthcare 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Nanotechnology for Healthcare 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Nanotechnology for Healthcare 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Nanotechnology for Healthcare 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Nanotechnology for Healthcare 麻豆原创 Size (2018-2029)
9.2 Latin America Nanotechnology for Healthcare 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Nanotechnology for Healthcare 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Nanotechnology for Healthcare 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Nanotechnology for Healthcare 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Nanotechnology for Healthcare 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Nanotechnology for Healthcare 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Nanotechnology for Healthcare 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Nanotechnology for Healthcare Introduction
11.1.4 Amgen Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.1.5 Amgen Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Detail
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Nanotechnology for Healthcare Introduction
11.2.4 Teva Pharmaceuticals Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Abbott
11.3.1 Abbott Company Detail
11.3.2 Abbott Business Overview
11.3.3 Abbott Nanotechnology for Healthcare Introduction
11.3.4 Abbott Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.3.5 Abbott Recent Development
11.4 UCB
11.4.1 UCB Company Detail
11.4.2 UCB Business Overview
11.4.3 UCB Nanotechnology for Healthcare Introduction
11.4.4 UCB Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.4.5 UCB Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Nanotechnology for Healthcare Introduction
11.5.4 Roche Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Nanotechnology for Healthcare Introduction
11.6.4 Celgene Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.6.5 Celgene Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Nanotechnology for Healthcare Introduction
11.7.4 Sanofi Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.7.5 Sanofi Recent Development
11.8 Merck & Co
11.8.1 Merck & Co Company Detail
11.8.2 Merck & Co Business Overview
11.8.3 Merck & Co Nanotechnology for Healthcare Introduction
11.8.4 Merck & Co Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.8.5 Merck & Co Recent Development
11.9 Biogen
11.9.1 Biogen Company Detail
11.9.2 Biogen Business Overview
11.9.3 Biogen Nanotechnology for Healthcare Introduction
11.9.4 Biogen Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.9.5 Biogen Recent Development
11.10 Stryker
11.10.1 Stryker Company Detail
11.10.2 Stryker Business Overview
11.10.3 Stryker Nanotechnology for Healthcare Introduction
11.10.4 Stryker Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.10.5 Stryker Recent Development
11.11 Gilead Sciences
11.11.1 Gilead Sciences Company Detail
11.11.2 Gilead Sciences Business Overview
11.11.3 Gilead Sciences Nanotechnology for Healthcare Introduction
11.11.4 Gilead Sciences Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.11.5 Gilead Sciences Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Detail
11.12.2 Pfizer Business Overview
11.12.3 Pfizer Nanotechnology for Healthcare Introduction
11.12.4 Pfizer Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.12.5 Pfizer Recent Development
11.13 3M Company
11.13.1 3M Company Company Detail
11.13.2 3M Company Business Overview
11.13.3 3M Company Nanotechnology for Healthcare Introduction
11.13.4 3M Company Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.13.5 3M Company Recent Development
11.14 Johnson & Johnson
11.14.1 Johnson & Johnson Company Detail
11.14.2 Johnson & Johnson Business Overview
11.14.3 Johnson & Johnson Nanotechnology for Healthcare Introduction
11.14.4 Johnson & Johnson Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.14.5 Johnson & Johnson Recent Development
11.15 Smith & Nephew
11.15.1 Smith & Nephew Company Detail
11.15.2 Smith & Nephew Business Overview
11.15.3 Smith & Nephew Nanotechnology for Healthcare Introduction
11.15.4 Smith & Nephew Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.15.5 Smith & Nephew Recent Development
11.16 Leadiant Biosciences
11.16.1 Leadiant Biosciences Company Detail
11.16.2 Leadiant Biosciences Business Overview
11.16.3 Leadiant Biosciences Nanotechnology for Healthcare Introduction
11.16.4 Leadiant Biosciences Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.16.5 Leadiant Biosciences Recent Development
11.17 Kyowa Hakko Kirin
11.17.1 Kyowa Hakko Kirin Company Detail
11.17.2 Kyowa Hakko Kirin Business Overview
11.17.3 Kyowa Hakko Kirin Nanotechnology for Healthcare Introduction
11.17.4 Kyowa Hakko Kirin Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.17.5 Kyowa Hakko Kirin Recent Development
11.18 Shire
11.18.1 Shire Company Detail
11.18.2 Shire Business Overview
11.18.3 Shire Nanotechnology for Healthcare Introduction
11.18.4 Shire Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.18.5 Shire Recent Development
11.19 Ipsen
11.19.1 Ipsen Company Detail
11.19.2 Ipsen Business Overview
11.19.3 Ipsen Nanotechnology for Healthcare Introduction
11.19.4 Ipsen Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.19.5 Ipsen Recent Development
11.20 Endo International
11.20.1 Endo International Company Detail
11.20.2 Endo International Business Overview
11.20.3 Endo International Nanotechnology for Healthcare Introduction
11.20.4 Endo International Revenue in Nanotechnology for Healthcare Business (2018-2023)
11.20.5 Endo International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Amgen
Teva Pharmaceuticals
Abbott
UCB
Roche
Celgene
Sanofi
Merck & Co
Biogen
Stryker
Gilead Sciences
Pfizer
3M Company
Johnson & Johnson
Smith & Nephew
Leadiant Biosciences
Kyowa Hakko Kirin
Shire
Ipsen
Endo International

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.